ArticleLupus science & medicine2026
Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the prognostic value of echocardiographic parameters for major adverse cardiovascular and cerebrovascular events (MACCE) in SLE patients.
methodsThis study was designed as a retrospective cohort trial that enrolled 286 patients with SLE and 64 individuals from a health examination cohort as controls between January 2014 and December 2024. Transthoracic echocardiography was performed to measure cardiac structural parameters; clinical and laboratory data were also collected to assess disease activity, and the Left Ventricular Mass Index (LVMI) was calculated. The primary endpoint was MACCE. Propensity score matching was applied to reduce confounding bias. Independent risk factors were identified using Cox proportional hazards regression models, and the optimal cut-off value for LVMI was determined via receiver operating characteristic (ROC) curve analysis. Subsequently, patients were stratified based on this cut-off, and Kaplan-Meier survival curves with Log-rank tests were plotted to compare intergroup differences in survival outcomes.
resultsCompared with the control group, patients with SLE were significantly associated with aortic root (p=0.002), right ventricular internal dimension in diastole (RVDd, p=0.038), interventricular septal thickness (IVST, p=0.033), left ventricular posterior wall thickness (LVPWT, p<0.001), LVM (p=0.025), LVMI (p=0.007) left ventricular posterior wall motion amplitude (LVPWMA, p=0.017) and interventricular septal motion amplitude (IVSMA, p=0.004). Multivariate Cox proportional hazards analysis further identified RVDd (p=0.027), LVMI (p=0.017), low-density lipoprotein (p=0.036) as independent predictors for MACCE in the SLE cohort. ROC curve analysis determined an optimal LVMI cut-off of 101.7 g/m² for predicting adverse outcomes, yielding an area under the curve (AUC) of 0.751 (95% CI 0.653 to 0.849), with 76.9% sensitivity and 64.6% specificity.
conclusionsCompared to the control group, patients with SLE showed significantly higher LVM and LVMI. LVMI was identified as an independent risk factor for MACCE in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.